Ritu Baral
Stock Analyst at TD Cowen
(2.45)
# 2,527
Out of 5,090 analysts
39
Total ratings
53.12%
Success rate
10.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ritu Baral
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Buy | $223 → $231 | $204.92 | +12.73% | 5 | Nov 20, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $65 → $97 | $99.25 | -2.27% | 2 | Nov 6, 2025 | |
| RNA Avidity Biosciences | Downgrades: Hold | $78 → $74 | $71.71 | +3.19% | 2 | Oct 29, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $35 → $39 | $27.55 | +41.56% | 2 | Sep 11, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $390 → $554 | $574.52 | -3.57% | 2 | Aug 26, 2025 | |
| AKRO Akero Therapeutics | Initiates: Buy | $76 | $54.48 | +39.51% | 1 | Aug 4, 2025 | |
| SPRO Spero Therapeutics | Downgrades: Hold | n/a | $2.29 | - | 4 | Nov 18, 2024 | |
| ANTX AN2 Therapeutics | Downgrades: Hold | n/a | $1.03 | - | 2 | Nov 18, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $282 → $371 | $456.88 | -18.80% | 4 | Oct 21, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | n/a | $6.21 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $175 | $22.36 | +682.65% | 1 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $80.86 | - | 2 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.66 | - | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $15.05 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.38 | - | 2 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $45.98 | - | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $29.19 | - | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.27 | - | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.03 | - | 2 | Jul 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $548.73 | - | 2 | Jan 12, 2018 |
Insmed
Nov 20, 2025
Maintains: Buy
Price Target: $223 → $231
Current: $204.92
Upside: +12.73%
Palvella Therapeutics
Nov 6, 2025
Maintains: Buy
Price Target: $65 → $97
Current: $99.25
Upside: -2.27%
Avidity Biosciences
Oct 29, 2025
Downgrades: Hold
Price Target: $78 → $74
Current: $71.71
Upside: +3.19%
ACADIA Pharmaceuticals
Sep 11, 2025
Maintains: Buy
Price Target: $35 → $39
Current: $27.55
Upside: +41.56%
Madrigal Pharmaceuticals
Aug 26, 2025
Maintains: Buy
Price Target: $390 → $554
Current: $574.52
Upside: -3.57%
Akero Therapeutics
Aug 4, 2025
Initiates: Buy
Price Target: $76
Current: $54.48
Upside: +39.51%
Spero Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.29
Upside: -
AN2 Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.03
Upside: -
Alnylam Pharmaceuticals
Oct 21, 2024
Maintains: Buy
Price Target: $282 → $371
Current: $456.88
Upside: -18.80%
Sagimet Biosciences
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $6.21
Upside: -
Mar 22, 2023
Maintains: Outperform
Price Target: $125 → $175
Current: $22.36
Upside: +682.65%
Nov 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $80.86
Upside: -
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.66
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $15.05
Upside: -
Jul 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.38
Upside: -
Jun 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $45.98
Upside: -
Mar 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $29.19
Upside: -
Jun 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.27
Upside: -
Jul 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $3.03
Upside: -
Jan 12, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $548.73
Upside: -